A randomised phase 1 study to investigate safety, pharmacokinetics and impact on gut microbiota following single and multiple oral doses in healthy male subjects of SMT19969, a novel agent for Clostridium difficile infections

Table 6 Composition of SMT19969 and metabolites in faeces of three subjects from Group G

Name	% of Total Peak Area
	Subject 1		Subject 2		Subject 3
	Day 5	Day 10	Day 5	Day 10	Day 5	Day 10
SMT19969	99.05	99.34	99.21	100.00	97.99	97.72
Total metabolites	0.95	0.66	0.79	0.00	2.01	2.28

ISSN: 1471-2334